MeMed ’s Post

🚀 Discover the impact of MeMed BV on enhancing #antibioticstewardship and improving patient outcomes in #sepsis care. In the fight against #sepsis, every second counts. MeMed BV empowers clinicians with the precision to swiftly differentiate between bacterial and viral infections, ensuring timely and accurate treatment decisions. 👀 Watch the video to learn more! https://lnkd.in/d_n7qTzd Alon Angel #MeMedBV #SepsisAwareness #PatientCare 

🔬 Whether it's a common cold or something more serious, understanding what's making us sick is crucial. You don't need to be an #infectiousdisease specialist to know that #viruses and #bacteria are often behind our illnesses. But distinguishing between these two is vital—especially when it comes to prescribing the right treatment. 👉 Our first #blog post by Jeroen Stas dives deep into the critical question: "Is it bacterial or is it viral?" Knowing the answer is foundational in deciding whether to prescribe antibiotics. 🌐 Read below to learn more about how advanced diagnostic technologies are essential in making these crucial distinctions, ultimately guiding better treatment decisions and promoting #antimicrobialstewardship. ➡️ https://lnkd.in/d7PV5wp7

🎯 Integrating MeMed BV into your sepsis protocol. Upgrade your sepsis response to accurately pinpoint bacterial vs. viral infections, reducing misdiagnoses and unnecessary hospital stays. Improve patient care, optimize workflows, and lower costs. 3️⃣ reasons why MeMed BV: ✔️        Precision: Quicker, more accurate diagnostic and treatment decisions. ✔️        Improved Patient Management: Reduced unnecessary interventions. ✔️        Cost-Effective: Significant cost savings and improved patient outcomes. Act now to make a significant impact in the battle against sepsis! #SepsisAwareness #MedicalInnovation #HealthcareTechnology #MeMedBV #PatientCare https://lnkd.in/dNRdgxMe

♨️♨️♨️ NEW STUDY! The double-blinded diagnostic accuracy study, "Apollo," showcased the effectiveness of the rapid host-response test, MeMed BV, in differentiating bacterial from viral infections in both children and adults. Take home messages: 🎯 First study including US patients from various acute care settings. MeMed BV achieved sensitivity of 90%, specificity of 93%, and an NPV of 99%. ⏲️ First study validating performance on the MeMed Key, the rapid immunoassay platform measuring BV test within 15 min. 📈  Actionable MeMed BV results were obtained in 73% of cases that a panel of experts classified as indeterminate infection etiology. 💊 MeMed BV could potentially have reduced unwarranted antibiotic prescription by a 2.2-fold. Big thanks to the lead authors Richard G Bachur, Boston Children's Hospital, Richard E. Rothman, Johns Hopkins Hospital, Sheldon Kaplan, Texas Children's Hospital, and all the many contributors involved in this study for their relentless dedication and resilience. Read the full study published in [Jacep Open] here: https://lnkd.in/dSbgHYZT American College of Emergency Physicians

📢 We're thrilled to announce the expansion of our partnership with Beckman Coulter Diagnostics as authorized distributors of our MeMed BV® assay and MeMed Key®. This progress is a continuation of our original joint development collaboration, extending the use of the MeMed BV-based assay for Beckman Coulter Access Immunoassay Analyzers. Kevin O'Reilly, President of Beckman Coulter, stated: "Beckman Coulter is committed to advancing diagnostics that provide insights into an individual's immune response. We're excited to extend our partnership with MeMed, expanding the impact of the MeMed Key and MeMed BV assay." Eran Eden, MeMed's CEO and co-founder, added: "We're thrilled to expand our partnership with Beckman Coulter. This expansion aims to accelerate the adoption of MeMed BV and broaden patient access through a strategic hub and spoke model." By leveraging the capabilities of Beckman Coulter's analyzers, we're creating an ecosystem that will aid clinicians in distinguishing between bacterial and viral infections with unprecedented ease and precision. This partnership will enable us to impact more patient lives with our BV technology, improving patient care and outcomes. We look forward to the positive impact this expanded partnership will have on healthcare providers and patients alike. 🚀 #MeMed #BeckmanCoulter #Partnership #Innovation #Diagnostics #Healthcare Read the full press release 👇 https://lnkd.in/dnwDm5Gi

📢Calling all #ECCMID24 attendees! Join Jack Schneider, MD, Indiana University School of Medicine, in Arena 3 in 15 minutes, for his Flash talk (E poster) presentation, where he will discuss the assessment of potential clinical impact of a rapid host-response test for differentiating bacterial and viral infections in children. 

🌟 Day 2 at #ECCMID24 🌟 If you're walking the floors of #ECCMID, don't forget to stop by booth #E73 where our team is showcasing the MeMed BV diagnostic test, first to receive both FDA and CE-IVDR clearance, which accurately differentiates between bacterial and viral infections in just 15 minutes. 🔬 Don’t miss our live case simulator where you can see the MeMed BV test in action and explore its practical applications and benefits firsthand. Looking forward to connecting with you and sharing how we can transform patient care together!

Are you at #ECCMID2024? In just one hour several exciting abstracts will be presented. Head over to the poster zone for one-on-one conversations about the research, methodology, results, and potential implications. Don't miss out! #P3892: Tanya Gottlieb, PhD, Maccabi Health care Services will discuss the real-world impact of MeMed BV, a rapid host response test for distinguishing bacterial and viral infections, in an urgent care network. #P3877: Jeroen Stas, PhD, York Health Economics Consortium will present the potential of a host-response diagnostic test for differentiating bacterial from viral infections to improve the lower respiratory tract infections care pathway in the NHSL a qualitive evaluation. #P2248: Sriram Ramgopal, MD, Ann & Robert H. Lurie Children's Hospital of Chicago Children’s Hospital, Northwestern University Feinberg School of Medicine will he discuss the association of host signature based on TRAIL, IP-10, and CRP with pediatric pneumonia. #Research #HostResponse

Don't miss MeMed at #AAEM24! If you're heading to Austin, be sure to stop by booth #114 to see a demonstration of MeMed BV. It's the first FDA-cleared test that distinguishes between bacterial and viral infections in just 15 minutes. We look forward to meeting you there ya’ll!🌟